Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cryofocus Medtech (Shanghai) Co. Ltd. Class H ( (HK:6922) ) just unveiled an update.
Cryofocus Medtech reported a 30.7% increase in revenue for 2024, reaching RMB 53,531,000, despite a slight increase in losses. The company achieved significant milestones, including approvals for several cryoablation systems and strategic partnerships for research and distribution, which could enhance its market position and operational capabilities.
More about Cryofocus Medtech (Shanghai) Co. Ltd. Class H
Cryofocus Medtech (Shanghai) Co., Ltd. operates in the medical technology industry, focusing on cryoablation systems for various medical conditions. Their primary products include systems for atrial fibrillation, benign and malignant stenosis, and anti-gastroesophageal reflux, with a market focus on respiratory intervention products in mainland China.
YTD Price Performance: -36.27%
Average Trading Volume: 22,169
Technical Sentiment Signal: Buy
Learn more about 6922 stock on TipRanks’ Stock Analysis page.